Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of Congenital Nephrogenic Diabetes Insipidus With a Guanylate Cyclase Stimulator, Riociguat or a Phosphodiesterase Type 5 Inhibitor, Sildenafil

Trial Profile

Treatment of Congenital Nephrogenic Diabetes Insipidus With a Guanylate Cyclase Stimulator, Riociguat or a Phosphodiesterase Type 5 Inhibitor, Sildenafil

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jul 2018

At a glance

  • Drugs Riociguat (Primary) ; Sildenafil (Primary)
  • Indications Diabetes insipidus
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top